JP2023504233A - 酸化的ストレス損傷を低減又は防止するための製剤 - Google Patents

酸化的ストレス損傷を低減又は防止するための製剤 Download PDF

Info

Publication number
JP2023504233A
JP2023504233A JP2022524952A JP2022524952A JP2023504233A JP 2023504233 A JP2023504233 A JP 2023504233A JP 2022524952 A JP2022524952 A JP 2022524952A JP 2022524952 A JP2022524952 A JP 2022524952A JP 2023504233 A JP2023504233 A JP 2023504233A
Authority
JP
Japan
Prior art keywords
combination
quercetin
alpha
acid
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022524952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504233A5 (https=
Inventor
マーフィー キーラン
ケリンズ フェルガル
アンドリュー タルノポルスキー マーク
Original Assignee
コラ セラピューティクス インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コラ セラピューティクス インコーポレイティド filed Critical コラ セラピューティクス インコーポレイティド
Publication of JP2023504233A publication Critical patent/JP2023504233A/ja
Publication of JP2023504233A5 publication Critical patent/JP2023504233A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06—Benzopyran radicals
    • C07H17/065—Benzo[b]pyrans
    • C07H17/07—Benzo[b]pyran-4-ones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Sealing Material Composition (AREA)
  • Medicinal Preparation (AREA)
JP2022524952A 2019-10-28 2020-10-27 酸化的ストレス損傷を低減又は防止するための製剤 Pending JP2023504233A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926953P 2019-10-28 2019-10-28
US62/926,953 2019-10-28
PCT/CA2020/051439 WO2021081634A1 (en) 2019-10-28 2020-10-27 Formulation to reduce or prevent oxidative stress damage

Publications (2)

Publication Number Publication Date
JP2023504233A true JP2023504233A (ja) 2023-02-02
JP2023504233A5 JP2023504233A5 (https=) 2023-11-06

Family

ID=75714707

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524952A Pending JP2023504233A (ja) 2019-10-28 2020-10-27 酸化的ストレス損傷を低減又は防止するための製剤

Country Status (8)

Country Link
US (1) US20220378716A1 (https=)
EP (1) EP4051261A4 (https=)
JP (1) JP2023504233A (https=)
KR (1) KR20220132522A (https=)
CN (1) CN115209892B (https=)
AU (1) AU2020376980B2 (https=)
IL (1) IL292525A (https=)
WO (1) WO2021081634A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118121587A (zh) * 2022-12-02 2024-06-04 辽宁何氏医学院 二氢槲皮素在治疗眼表疾病中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
JP2004515508A (ja) * 2000-12-16 2004-05-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 化合物の健康促進組成物
JP2015218140A (ja) * 2014-05-19 2015-12-07 医療法人千清會 鈴木脳神経外科 抗酸化サプリメント

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280093A1 (en) * 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
US6248375B1 (en) * 2000-03-14 2001-06-19 Abbott Laboratories Diabetic nutritionals and method of using
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US6572897B1 (en) * 2002-07-03 2003-06-03 Vitacost.Com, Inc. Insulin sensitivity maintenance and blood sugar level maintenance formulation for the prevention and treatment of diabetes
US9192586B2 (en) * 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
WO2004064725A2 (en) * 2003-01-13 2004-08-05 The Quigley Corporation Oral compositions and methods for treatment of adverse effects or radiation
US7399496B2 (en) * 2003-02-07 2008-07-15 Glanbia Nutritionals (Ireland) Limited Hydrolyzed whey protein compositions
US20050112210A1 (en) * 2003-09-12 2005-05-26 Terry Grossman Eye nutritional supplement
US7585536B2 (en) * 2004-05-27 2009-09-08 Silver Barnard S Compositions of fructose and glucose containing inulin
US20060115556A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
US20060115554A1 (en) * 2004-12-01 2006-06-01 Slim-Fast Foods Company, Division Of Conopco, Inc. Nutrition bar
US20070082025A1 (en) * 2005-10-07 2007-04-12 Catani Steven J Methods for achieving and maintaining weight loss
US7976879B2 (en) * 2005-11-04 2011-07-12 Roizen Michael F Nutritional supplement product to suppress age-related decline in cognitive capacity and other aging functions
CN101835449A (zh) * 2007-08-31 2010-09-15 Dsmip资产有限公司 4-脒基苄胺用于美容和/或皮肤病学的用途
US8491889B1 (en) * 2010-01-26 2013-07-23 Jayson B. Calton Method for reducing micronutrient competitions
AU2011227202A1 (en) * 2010-03-17 2012-10-04 Arbonne International Llc Oral supplement
CN102232553A (zh) * 2010-05-06 2011-11-09 袁长铭 摄养组合物质
US8344078B2 (en) * 2010-05-21 2013-01-01 Chevron Phillips Chemical Company Lp Continuous take off technique and pressure control of polymerization reactors
EP2397038A1 (en) * 2010-06-21 2011-12-21 Abbott Laboratories Early programming of brain function through soy protein feeding
US20130224281A1 (en) * 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
US20140023701A1 (en) * 2011-04-07 2014-01-23 Nugevity Llc Method and Composition for Ameliorating the Effects tor a Subject Exposed to Radiation or Other Sources of Oxidative Stress
CA2799127C (en) * 2012-12-18 2021-05-18 Matthew Bennett Compositions and methods for treating traumatic brain injury
US9101580B2 (en) * 2012-12-18 2015-08-11 Matthew Bennett Compositions and methods for treating traumatic brain injury
JP7123945B2 (ja) * 2016-10-03 2022-08-23 シャー，ホウン・サイモン がん放射線療法を増強するための組成物および方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515508A (ja) * 2000-12-16 2004-05-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 化合物の健康促進組成物
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
JP2015218140A (ja) * 2014-05-19 2015-12-07 医療法人千清會 鈴木脳神経外科 抗酸化サプリメント

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
化学と生物, vol. 40, no. 1, JPN6024039367, 2002, pages 15 - 21, ISSN: 0005764823 *

Also Published As

Publication number Publication date
WO2021081634A1 (en) 2021-05-06
CA3159328A1 (en) 2021-05-06
IL292525A (en) 2022-06-01
CN115209892B (zh) 2025-09-12
CN115209892A (zh) 2022-10-18
EP4051261A1 (en) 2022-09-07
EP4051261A4 (en) 2023-08-02
AU2020376980B2 (en) 2026-01-15
KR20220132522A (ko) 2022-09-30
US20220378716A1 (en) 2022-12-01
AU2020376980A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
Kuntić et al. Radioprotectors–the evergreen topic
AU2002309615B2 (en) Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
Sofic et al. Antioxidant capacity of the neurohormone melatonin
US20030118536A1 (en) Topical compositions and methods for treatment of adverse effects of ionizing radiation
ZA200403365B (en) Topical compositions and methods for treatment of adverse effects of ionizing radiation
Adhikari et al. Nano-silymarin provides protection against γ-radiation-induced oxidative stress in cultured human embryonic kidney cells
JP4411414B2 (ja) 糖尿病性神経障害の治療に対する組成物及びその方法
BRPI0513673B1 (pt) Método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
US10220018B2 (en) Method of mitigating long and short term detrimental effects of exposure to low dose ionizing radiation by administration of genistein
de Moraes Ramos et al. Evaluation of radioprotective effect of vitamin E in salivary dysfunction in irradiated rats
Muid et al. Optimal antioxidant activity with moderate concentrations of Tocotrienol rich fraction (TRF) in in vitro assays.
AU2020376980B2 (en) Formulation to reduce or prevent oxidative stress damage
Ortmann et al. Effect of antioxidant vitamins on radiation-induced apoptosis in cells of a human lymphoblastic cell line
WO2004064725A2 (en) Oral compositions and methods for treatment of adverse effects or radiation
CA3159328C (en) Formulation to reduce or prevent oxidative stress damage
WO2015077656A1 (en) Novel antioxidant formulations
JP2023504233A5 (https=)
US12005092B2 (en) Herbal composition for breast cancer prevention
JP5080011B2 (ja) グルタチオンペルオキシダーゼ活性を増加させるための組成物
Nooreen et al. Recent Advances in Natural Phytocompounds for the Chemotherapeutic Management of Head and Neck Squamous Cell Carcinoma from 2018–2024
Qining et al. Apoptotic effect of combination of epalrestat and palmitic acid in cholangiocarcinoma RBE cells
Kosowski et al. Vitamin E: natural vs. synthetic
Tavartkiladze et al. AminoTriComplex: Preclinical and Clinical Evidence for a Multi-Component Phytochemical Formulation Targeting Oxidative Stress, Mitochondrial Function, and Cancer-Related Pathways

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20220624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231026

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260106